Ignite Creation Date:
2025-12-24 @ 12:35 PM
Ignite Modification Date:
2026-01-08 @ 7:03 PM
Study NCT ID:
NCT03486561
Status:
UNKNOWN
Last Update Posted:
2018-04-03
First Post:
2018-03-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
Sponsor:
OBS Pakistan
Organization:
Study Overview
Official Title:
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
Status:
UNKNOWN
Status Verified Date:
2018-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MIDA
Brief Summary:
The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: